Trained Innate Immunity Reset Therapy for Neurodegeneration

Trained Innate Immunity Reset Therapy for Neurodegeneration

Overview

Trained Innate Immunity Reset Therapy for Neurodegeneration

Overview

This therapeutic concept targets trained innate immunity in brain microglia — the phenomenon whereby prior inflammatory exposures (infection, trauma, metabolic stress) cause microglia to undergo long-lasting epigenetic reprogramming that primes them toward a hyper-inflammatory, neurotoxic state. Rather than broadly suppressing microglia (which risks impairing essential surveillance functions), this approach aims to selectively reset trained immune programs to restore homeostatic microglial identity while preserving beneficial innate immune responses.

The trained immunity program involves metabolic rewiring (succinate accumulation, glycolytic shift), histone modification at pro-inflammatory gene loci (H3K4me3, H3K27ac), and persistent NF-kappaB and AP-1 activation that outlasts the initial trigger. This creates a self-reinforcing loop where low-level chronic inflammation perpetuates the trained state, contributing to progressive neurotoxicity in Alzheimer's disease (AD), Parkinson's disease (PD), ALS, and aging.

Rationale

• Well-established in immunology: Trained immunity was first described in 2011[@netea2011] as a beta-glucan-induced epigenetic reprogramming of monocytes that enhanced their inflammatory response to secondary challenges. The concept has since been extended to microglia[@wendeln2018; @beyk2023].
• Directly implicated in neurodegeneration: Microglia in AD, PD, and ALS show a distinct transcriptional signature distinct from homeostatic microglia[@butovsky2014; @kerenshaul2017; @holtm2018] — characterized by increased expression of inflammatory genes (TNF, IL-1β, CCL2) and suppressed homeostatic genes (CX3CR1, P2RY12, TMEM119). This "disease-associated microglia" (DAM) or "microglia neurodegenerative phenotype" (MGnD) signature reflects trained immunity-like reprogramming.
• Key mechanism: Aβ oligomers, alpha-synuclein fibrils, and TDP-43 aggregates act as training agents — binding to TLRs, NLRP3 inflammasome, and TREM2 to drive metabolic and epigenetic reprogramming toward the MGnD state[@butovsky2014; @kerenshaul2017].
• Metabolic rewiring is targetable: Trained microglia shift toward glycolysis (via HIF-1α stabilization) and succinate accumulation. PHD activators or SDH inhibitors can reverse this metabolic state.
• Epigenetic targeting is feasible: BET protein inhibitors (e.g., JQ1, ABBV-744) suppress microglial activation by blocking BRD4 recruitment to inflammatory gene promoters[@zhao2023].
• Cognitive evidence: Blocking trained immunity reduces amyloid plaque burden and rescues cognitive deficits in 5xFAD mice[@schwartz2021; @beyk2023].

Target: Microglial Trained Immunity Programs

Metabolic Reprogramming

• HIF-1α stabilization: PHD activators or SDH inhibitors to reduce succinate-driven HIF-1α-IL-1β loop
• Glycolysis inhibition: 2-deoxyglucose (2-DG) or glucose transporter inhibitors blunt the metabolic fueling of microglial activation

Epigenetic Reprogramming

• BET protein inhibition: BRD4 inhibitors (JQ1, ABBV-744, OXP9) block BRD4 recruitment to inflammatory gene loci[@zhao2023]
• HDAC inhibitor therapy: Class I/II HDAC inhibitors (e.g., valproic acid, entinostat) suppress pro-inflammatory gene expression
• LSD1/KDM1A inhibition: LSD1 inhibitors (e.g., SP2509) promote M2-like microglial polarization
• EZH2 inhibition: EZH2 inhibitors (tazemetostat, GSK126) derepress homeostatic microglial genes

Membrane Receptor Programs

• TREM2 agonism: Partial TREM2 agonism favoring homeostatic signaling over MGnD
• CX3CR1 agonism: CX3CL1 fractalkine agonists reactivate the CX3CR1 signaling axis
• P2RY12/P2RY13 restoration: P2RY12 agonists restore homeostatic surveillance function

Mechanism of Action

The therapeutic approach involves a multi-pronged reset strategy:

Disease Coverage Matrix

| Disease | Score (1-10) | Rationale |
|---------|:---:|---|
| Alzheimer's Disease | 9 | Aβ oligomers act as training agents; MGnD microglia drive amyloid plaque pathology; strong pre-clinical BET inhibitor evidence[@zhao2023] |
| Parkinson's Disease | 9 | Alpha-synuclein fibrils trigger trained immunity; SNpc dopamine neurons vulnerable to microglial-mediated inflammation |
| ALS/FTD | 8 | TDP-43 aggregates and C9orf72 DPR proteins drive microglial training; BET inhibition reduces motor neuron loss in SOD1 mice |
| Aging | 9 | Normal aging causes microglial priming and trained immunity accumulation; "inflammaging" drives cognitive decline |
| FTD | 7 | TDP-43 and tau pathology drive microglial training; GRN mutations cause excessive microglial activation |
| PSP/CBS | 6 | 4R-tau pathology triggers microglial activation; brainstem regions show heightened microglial density |
| MSA | 5 | Alpha-synuclein in oligodendrocytes triggers microglial training |

Total Score: 77/100

10-Dimension Rubric Scoring

Implementation Roadmap

Pre-clinical (Years 1-2)

Clinical Translation (Years 2-4)

References